NICE will appraise Tolvaptan
The Department of Health has asked NICE - the National Institute for Health and Care Excellence - to conduct an appraisal of tolvaptan for treating ADPKD (autosomal dominant polycystic kidney disease). The date of the appraisal meeting will be 1st April 2015.
The PKD Charity has been invited to make a submission to NICE about patient and carer experience of living with ADPKD. The submission will also include information from people who have been on the tolvaptan drug trials in the UK.
If tolvaptan receives 'marketing authorisation' from the EMA and the outcome of the appraisal is positive, NICE will recommend the use of tolvaptan within the NHS.